Alar Pharmaceuticals Inc

Alar Pharmaceuticals Inc maintains a strong liquidity position with a current ratio of 35.07, indicating a significant buffer of current assets relative to current liabilities. The company's cash and equivalents amount to 559,063,000 TWD, which supports its operational flexibility and financial stability. The price-to-book ratio of 3.25 suggests that the market values the company at a premium to its book value, reflecting investor confidence in its intangible assets and future earnings potential.

In terms of profitability, Alar Pharmaceuticals Inc reported a net income of 12,049,000 TWD, but experienced an operating loss of 22,106,000 TWD. The return on equity of 0.47% and return on assets of 0.45% indicate that the company is generating modest returns relative to its equity and asset base. These metrics are below the typical thresholds for pharmaceutical companies, which often require higher returns to justify the high R&D expenditures and long development cycles.

The company's revenue is not disclosed in the latest financial snapshot, making it difficult to assess geographic and segment exposure. However, the absence of detailed segment data suggests that Alar Pharmaceuticals Inc may have a concentrated business model, potentially increasing its vulnerability to market-specific risks.

Looking at the growth trajectory, the company's operating cash flow of 9,987,000 TWD and free cash flow of 11,957,000 TWD indicate a positive cash flow generation capability. However, the lack of revenue data and the operating loss suggest that the company is in a growth phase with significant investment in R&D and product development.

The risk assessment for Alar Pharmaceuticals Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is characterized by minimal debt, with long-term debt amounting to only 1,082,000 TWD. This conservative approach to debt management reduces financial leverage and interest rate exposure.

Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial snapshot does not include recent events or transcripts, suggesting that there are no material developments to report at this time.

The company maintains a zero debt-to-equity ratio, significantly exceeding the 75th percentile of its pharmaceutical peer cohort.

Alar Pharmaceuticals faces low dilution risk, suggesting current equity holders are protected from significant share count expansion.

The firm exhibits low liquidity risk, indicating sufficient short-term assets to meet immediate financial obligations comfortably.

The company carries a high credit risk flag, raising concerns about its ability to service debt or secure financing.

Return on equity of 0.47% falls well below the 2.92% median for the pharmaceutical cohort, indicating poor capital efficiency.